User profiles for Sivan Gazit
 | Sivan GazitHead of Research, Kahn Sagol Maccabi Research and Innovation Center, Maccabi … Verified email at mac.org.il Cited by 3094 |
[HTML][HTML] Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Background Reports of waning vaccine-induced immunity against COVID-19 have begun to
surface. With that, the comparable long-term protection conferred by previous infection with …
surface. With that, the comparable long-term protection conferred by previous infection with …
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely …
[HTML][HTML] Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19)
vaccines might reduce viral load in breakthrough infection and thereby further …
vaccines might reduce viral load in breakthrough infection and thereby further …
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
The effectiveness of the coronavirus disease 2019 (COVID-19) BNT162b2 vaccine in preventing
disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing…
disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing…
Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine
Importance With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-BioNTech),
a nationwide third-dose (booster) vaccination campaign was initiated in Israel …
a nationwide third-dose (booster) vaccination campaign was initiated in Israel …
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting
individuals who have been vaccinated against the disease and possibly lowering the likelihood …
individuals who have been vaccinated against the disease and possibly lowering the likelihood …
Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
Importance The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III
randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. …
randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. …
The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data
Background Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines
were shown to be highly efficacious in preventing the disease in randomized controlled trials; …
were shown to be highly efficacious in preventing the disease in randomized controlled trials; …
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
The effectiveness of vaccines against COVID-19 on the individual level is well established.
However, few studies have examined vaccine effectiveness against transmission. We used a …
However, few studies have examined vaccine effectiveness against transmission. We used a …
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …
